Executive Program in Pharmaceutical Business

In today's rapidly evolving pharmaceutical landscape, leaders face unprecedented challenges and opportunities. The End-to-End Executive Program is designed to equip senior pharmaceutical executives with the knowledge, skills, and network to drive meaningful change and create lasting impact across the entire value chain of pharmaceutical medicine.

This transformative educative journey combines cutting-edge academic insights with real-world practicality, delivered through a powerful blend of in-person intensives, interactive online learning, and a capstone Healthcare Impact Project. The program covers the full spectrum of pharmaceutical medicine, from early-stage research and development through to commercialization and market access strategies providing uptodate insights on how latest technological advancements are transforming this business.

The Executive Program in Pharmaceutical Business is a high-impact learning experience designed for professionals seeking a comprehensive, end-to-end understanding of the biopharmaceutical industry. The program integrates scientific foundations, strategic decision-making, regulatory insight, and commercial execution to equip participants with the capabilities required to lead in a rapidly evolving healthcare landscape.

In an industry shaped by accelerating innovation, advanced technologies, complex regulatory frameworks, and increasing pressure on access and value, leaders must navigate the full product lifecycle with clarity and confidence. Through a modular structure spanning R&D, manufacturing, real-world evidence, market access, commercialization, and leadership, the program empowers participants to translate innovation into sustainable impact for patients, organizations, and health systems.

This opening module provides a high-level understanding of the biopharmaceutical ecosystem and its accelerating pace of innovation. Participants explore the forces that shape today’s market—from AI/ML and next-generation therapeutic modalities to evolving business models and public–private collaborations. Designed to build strategic awareness, the module equips learners with the context needed to interpret industry trends and make informed decisions across scientific, commercial, and policy domains.

This module delves into the scientific and operational foundations of early-stage drug development. It examines cutting-edge biology platforms, target discovery and validation, translational approaches, and key principles in safety pharmacology. Participants gain a holistic view of the R&D continuum, understanding how scientific hypotheses are transformed into viable clinical candidates and how risk is managed during preclinical assessment.

Here, participants explore the critical role of biopharmaceutical manufacturing in enabling quality, scale, and patient access. The module covers process development, scale-up strategies, GMP compliance, and emerging models such as continuous and smart manufacturing. By connecting technical, operational, and regulatory perspectives, learners appreciate how manufacturing excellence underpins successful product lifecycles.

This module examines how real-world data is reshaping regulatory science and post-market oversight. Participants learn how RWE informs approval decisions, labeling changes, and long-term safety monitoring. Through concrete methods and case examples, the module highlights how robust evidence generation and pharmacovigilance safeguard patient safety and strengthen clinical and commercial outcomes

Participants engage with the complex landscape that determines how therapies reach patients and secure sustainable reimbursement. The module unpacks global HTA processes, payer interactions, pricing and value frameworks, and the growing importance of public and governmental affairs. By integrating policy, economics, and strategy, learners develop a comprehensive view of market access as a driver of global health impact.

This module focuses on the mechanics of achieving successful drug launches and sustained commercial performance. From global and local marketing strategy to digital and omnichannel engagement, participants learn how to build impactful commercial plans. The module also addresses business development, M&A, and the expanding role of patient-centricity in shaping modern commercial models.

This module develops the interpersonal and organizational skills required to thrive in a complex, regulated, and highly cross-functional industry. Participants practice influencing without authority, managing high-performance teams, leading through uncertainty, and making sound decisions under pressure. The module strengthens leadership agility and prepares participants for senior-level responsibility.

In the final component, participants form cross-functional teams to design a full end-to-end strategy for a hypothetical drug or vaccine. Guided by tutors, teams integrate all aspects of the curriculum—science, manufacturing, evidence, access, policy, and commercialization—into a cohesive strategic plan from target identification to launch.

Participants should have a minimum of 10 years of experience and current strategic responsibilities in their organizations within the pharmaceutical-biotech sector.

Outcomes:

Strategic, cross-functional understanding of pharmaceutical business including drug development, clinical evaluation, approval and commercialization with leadership skills required to succeed in current changing healthcare ecosystem. The participant will be ready to face their current challenges with a transversal and Up-To-Date knowledge of what is needed to succeed in current pharmaceutical and healthcare ecosystem.